[1]范大为刘凯袁成刚杜晓媛.Beclin-1在肾癌组织中的表达及其临床意义[J].中华腔镜泌尿外科杂志(电子版),2015,(02):96-100.[doi:10.3877/cma.j.issn.1674-3253.2015.02.004 ]
　Fan Dawei,Liu Kai Yuan Chenggang,et al.Expression level and clinical significance of Beclin-1 in renal cell carcinoma[J].,2015,(02):96-100.[doi:10.3877/cma.j.issn.1674-3253.2015.02.004 ]
点击复制

Beclin-1在肾癌组织中的表达及其临床意义()
分享到：

中华腔镜泌尿外科杂志(电子版)[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2015年02期
页码:
96-100
栏目:
临床研究
出版日期:
2015-08-31

文章信息/Info

Title:
Expression level and clinical significance of Beclin-1 in renal cell carcinoma
作者:
范大为1; 2刘凯3袁成刚2杜晓媛 1
273500 辽宁，辽宁医学院病理教研室1；124114 辽宁，辽河油田总医院欢喜岭医院内科2，儿科3
Author(s):
Fan Dawei1;  2;  Liu Kai3 Yuan Chenggang2;  Du Xiaoyuan1.
1Department of Pathology, Liaoning medical college, Liaoning 273500, China; 2Internal Medicine, 3Pediatrics, Huanxiling Hospital, General Hospital of Liaohe Oil Company, Liaoning 124008,China
关键词:
肾细胞癌;  Beclin-1; 预后
DOI:
10.3877/cma.j.issn.1674-3253.2015.02.004
摘要:
目的研究 Beclin-1在肾癌中的表达及其临床意义。方法通过免疫组化检测肾癌中自噬相关基因 Beclin-1的表达情况，初步探讨 Beclin-1在肾癌组织中表达情况。并分析 Beclin-1表达与肾癌复发及生存时间的相关性；多因素分析探讨其是否为肾癌预后的独立危险因素。结果对 133例肾癌及 12癌旁组织进行检测，肾癌组织中 Beclin-1基因表达水平明显低于癌旁组织（ P<0.05）。Beclin-1基因阴性肾癌患者的复发率明显高于 Beclin-1基因阳性患者（ P=0.041）； Beclin-1阳性肾癌患者总体生存率明显高于 Beclin-1阴性肾癌患者（ P=0.008）。多因素分析显示，Beclin-1，肿瘤分级、分期及淋巴结转移与否是肾癌复发、死亡的独立预后因素。结论 Beclin-1低表达是肾癌预后不良的独立危险因素，它可能成为肾癌个体化治疗的潜在靶点。

参考文献/References:

[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J], CA Cancer J Clin, 61(2):69-90. [2] Bianchi M, Gandaglia G, Trinh QD, et al. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma[J]. Urol Oncol, 2014, 32(1): 46.e1-46, e7. [3] Wang J, Bayles KW. Programmed cell death in plants:lessons from bacteria[J]. Trends Plant Sci, 201318(3): 133-139. [4] Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis[J]. Cell Prolif, 45: 487-98, 2012 [5] Peter ME: Programmed cell death: Apoptosis meets necrosis [J]. Nature, 2011, 471: 310-312. [6] Berry DL, Baehrecke EH. Autophagy functions in programmed cell death[J]. Autophagy, 2008, 4(3): 359-360. [7] Gouttefangeas C, Stenzl A, Stevanovic S, et al: Immunotherapy of renal cell carcinoma [J]. Cancer Immunol Immunother, 2007, 56 (1):117-128. [8] Park JY, Choe M, Kang Y, et al. IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma [J]. Korean J Pathol,2014, 48(2): 108-116. [9] Garcia-Roig M, Ortiz N, Lokeshwar V: Molecular marker for predicting treatment response in advanced renal cell carcinoma:does the promise fulfill clinical need?[J]. Curr Urol Rep, 2014, 15(1): 375. [10] Tsutsumi H, Miyamoto C, Furuichi Y, et al. VHL tumor suppressor gene: its mutation and protein level in renal cell carcinoma [J].Oncol Rep, 10(5): 1357-1361. [11] Jiang Y, Zhang W, Kondo K, et al: Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways [J]. Mol Cancer Res, 2003, 1 (6):453-362. [12] Lidgren A, Hedberg Y, Grankvist K, et al: The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res, 2005,11(3): 1129-1135. [13] Ljungberg BJ, Jacobsen J, Rudolfsson SH, et al: Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma[J]. BJU Int, 2006, 98(3): 661-667. (1):117-128. [14] Bui MH, Visapaa H, Seligson D, et al: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma[J]. J Urol, 2004, 171(6 Pt 1): 2461-2466. [15] Rioux-Leclercq N, Turlin B, Bansard J, et al: Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma [J]. Urology, 2000, 55 (4): 501-555 [16] Phuoc NB, Ehara H, Gotoh T, et al. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma[J]. Urology, 2007, 69(5): 843-848. [17] Wrighton KH: Autophagy: Kinase crosstalk through beclin 1 [J]. Nat Rev Mol Cell Biol, 2013, 14(7): 402-403. [18] Kang R, Zeh HJ, Lotze MT, et al. The Beclin 1 network regulates autophagy and apoptosis[J]. Cell Death Differ, 18(4): 571-580. [19] Liang XH, Kleeman LK, Jiang HH, et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein[J]. J Virol, 1998, 72(11): 8586-8596. [20] Aita VM, Liang XH, Murty VV, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21[J]. Genomics, 1999 59(1): 59-65.

相似文献/References:

[1]湛海伦,高新,蔡育彬,等.腹腔镜肾癌根治术联合DC-CIK细胞免疫治疗的临床疗效[J].中华腔镜泌尿外科杂志(电子版),2007,(02):112.
　ZHAN Hai-lun,GAO Xin,CAI Yu-bing,et al.Clinical efficacy of laparoscopic radical nephrectomy combined DC-CIK cells immunotherapy in renal cell carcinoma[J].,2007,(02):112.
[2]张宇,刘东,胡岚亭,等.后腹腔镜与开放肾部分切除术治疗局限性肾癌的疗效比较[J].中华腔镜泌尿外科杂志(电子版),2013,(01):9.
　ZHANG Yu,LIU Dong,HU Lan-Ting,et al.Comparison of retroperitoneal laparoscopic and open partial nephrectomy in local renal cell carcinoma[J].,2013,(02):9.
[3]曹翔 甘卫东.Xp11.2 易位/TFE3 基因融合相关性肾细胞癌的认知[J].中华腔镜泌尿外科杂志(电子版),2014,(05):374.[doi:10.3877/cma.j.issn.1674-3253.2014.05.015 ]
[4]加素尔 ?吐尔,徐铭泽,唐钵,等.广东省医学会泌尿外科疑难病例多学科会诊（第14期）——左肾原发罕见恶性肿瘤并全身多处转移[J].中华腔镜泌尿外科杂志(电子版),2024,18(01):110.[doi:10.3877/cma.j.issn.1674-3253.2024.01.021]
　[J].,2024,18(02):110.[doi:10.3877/cma.j.issn.1674-3253.2024.01.021]
[5]邓新军,李正明,李文彬.广东省医学会泌尿外科疑难病例多学科会诊（第14期）——左肾原发恶性肿瘤并发于肺癌并脑转移[J].中华腔镜泌尿外科杂志(电子版),2024,18(01):114.[doi:10.3877/cma.j.issn.1674-3253.2024.01.022]
　[J].,2024,18(02):114.[doi:10.3877/cma.j.issn.1674-3253.2024.01.022]

备注/Memo

备注/Memo:
通讯作者：杜晓媛，Email:351844459@qq.com
更新日期/Last Update: 1900-01-01